Cue Biopharma, Inc.CUENASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+72.0%
5Y CAGR+108.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+72.0%/yr
Quarterly compound
5Y CAGR
+108.1%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
39x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 252.80% |
| Q3 2025 | -40.76% |
| Q2 2025 | -7.45% |
| Q1 2025 | 18.97% |
| Q4 2024 | -23.42% |
| Q3 2024 | -1.56% |
| Q2 2024 | -6.56% |
| Q1 2024 | -6.32% |
| Q4 2023 | 10.26% |
| Q3 2023 | -7.29% |
| Q2 2023 | 13.41% |
| Q1 2023 | -17.13% |
| Q4 2022 | 49.68% |
| Q3 2022 | -21.07% |
| Q2 2022 | -4.86% |
| Q1 2022 | -12.34% |
| Q4 2021 | 1.88% |
| Q3 2021 | 28.83% |
| Q2 2021 | -10.74% |
| Q1 2021 | 22.64% |
| Q4 2020 | 6.47% |
| Q3 2020 | -7.41% |
| Q2 2020 | -18.04% |
| Q1 2020 | 42.24% |
| Q4 2019 | 31.36% |
| Q3 2019 | -22.79% |
| Q2 2019 | -17.79% |
| Q1 2019 | 22.42% |
| Q4 2018 | -33.84% |
| Q3 2018 | 90.49% |
| Q2 2018 | -6.96% |
| Q1 2018 | -35.49% |
| Q4 2017 | 125.38% |
| Q3 2017 | 17.12% |
| Q2 2017 | 38.85% |
| Q1 2017 | 19.15% |
| Q4 2016 | 47.54% |
| Q3 2016 | 17.10% |
| Q2 2016 | -0.00% |
| Q1 2016 | 0.00% |